| 夏玉朝,李爽,周淑娟,等.利福霉素钠与利福平治疗肺结核安全性评价[J].安徽医药,2018,22(8):1582-1584. |
| 利福霉素钠与利福平治疗肺结核安全性评价 |
| The safety evaluation of rifamycin sodium and rifampicin in the treatment of tuberculosis |
| 投稿时间：2017-03-07 |
| DOI： |
| 中文关键词: 利福霉素钠 利福平 安全性 |
| 英文关键词: Rifamycin sodium Rifampicin Safety evaluation |
| 基金项目: |
|
| 摘要点击次数: 3554 |
| 全文下载次数: 792 |
| 中文摘要: |
| 目的 比较利福霉素钠和利福平在治疗肺结核中的安全性。方法 792例肺结核患者分为利福霉素钠组(393例)和利福平组(399例),治疗2个月后评价其安全性。结果 利福霉素钠不良反应发生率(12.47%),较利福平(18.29%)低,严重不良反应发生率:利福霉素钠为1.78%,利福平为5.76%,差异有统计学意义；主要表现为肝损伤、过敏反应、肾功能损伤、血细胞减少和消化道不适。结论 利福霉素钠的不良反应发生率和严重程度小于利福平,若患者不能耐受利福平,可考虑利福霉素钠作为替代治疗。 |
| 英文摘要: |
| Objective To compare the safety of rifamycin sodium with rifampicin for the treatment of tuberculosis (TB).Methods 792 TB patients were divided into the rifamycin sodium group (n=393) and the RIF group (n=399). The safety was evaluated after treatment for 2 months.Results The incidence of adverse reactions in the rifamycin sodium group (12.47%) was lower than the RIF group (18.29%) The incidence of serious ADR in the rifamycin sodium group was 1.78%, while the RIF group was 5.76%. The difference was statistically significant. The ADR included liver injury, anaphylactic reaction, renal injury, hypocytosis and di-gestive discomfort.Conclusion The incidence and severity of adverse reactions of rifamycin sodium is lower than rifampicin. Rifamycin sodium can be considered as a choice if rifampicin is not tolerated. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
